Cytiva to globally commercialise Culture’s Stratyx 250 bioreactor platform as both companies co-develop scalable formats, bridging 250 mL to 2,000 L with seamless Xcellerex-enabled scale-up for next-gen biomanufacturing.
Culture Biosciences, an expert in cloud-connected bioreactor technology, and Cytiva, a Danaher company and a leader in the life sciences industry, have expanded their strategic collaboration to include both hardware commercialization and technology development.
Building on an existing collaboration to offer a Cytiva 250mL consumable featuring a scaled-down version of its Xcellerex X-Platform technology for use with Culture’s Stratyx 250 system, the expanded relationship will now include global commercialization by Cytiva of Culture’s Stratyx 250 hardware and joint development of additional bioreactor formats.
Chris Williams, CEO, Culture Biosciences, says: “By aligning our innovative bioreactor technology with Cytiva’s global reach and leadership in bioprocessing, we are accelerating the future of digital bioprocessing.”
Cytiva will serve as the exclusive global distributor of Culture’s Stratyx 250 bioreactor platform and associated consumables. Cytiva’s global infrastructure and customer reach will help ensure broad access to this next-generation, small-scale bioprocessing technology. The companies will collaborate to expand the Stratyx product line. This expanded portfolio will feature consumables built with Cytiva’s Xcellerex X-Platform technology, enabling seamless scale-up from 250 mL to 2,000 liters—offering customers an integrated and scalable solution across their bioprocessing workflows.
Jon Van Pelt, Vice President and General Manager, Single Use Technologies, Cytiva, says: “Expanding our collaboration with Culture Biosciences will help us deliver smarter, scalable, and connected biomanufacturing systems for our customers.”
By combining Culture’s expertise in cloud-enabled, small-scale bioreactors with Cytiva’s global scale and bioprocessing leadership, the companies are poised to deliver a fully integrated solution—from benchtop to production scale—that empowers biopharma innovators to accelerate development timelines, improve data connectivity, and scale processes with confidence.
